Pramanik S, Pal P, Ray S. Non-alcoholic fatty liver disease in type 2 diabetes: Emerging evidence of benefit of peroxisome proliferator-activated receptors agonists and incretin-based therapies. World J Methodol 2024; 14(2): 91319 [DOI: 10.5662/wjm.v14.i2.91319]
Corresponding Author of This Article
Sayantan Ray, MBBS, MD, Assistant Professor, Department of Endocrinology, All India Institute of Medical Sciences, Bhubaneswar, Sijua, Patrapada, Bhubaneswar 751019, Odisha, India. sayantan.ray30@gmail.com
Research Domain of This Article
Endocrinology & Metabolism
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Methodol. Jun 20, 2024; 14(2): 91319 Published online Jun 20, 2024. doi: 10.5662/wjm.v14.i2.91319
Non-alcoholic fatty liver disease in type 2 diabetes: Emerging evidence of benefit of peroxisome proliferator-activated receptors agonists and incretin-based therapies
Subhodip Pramanik, Partha Pal, Sayantan Ray
Subhodip Pramanik, Department of Endocrinology, Neotia Getwel Multispecialty Hospital, Siliguri 734010, West Bengal, India
Partha Pal, Department of Medical Gastroenterology, Asian Institute of Gastroenterology, Hyderabad 500082, India
Sayantan Ray, Department of Endocrinology, All India Institute of Medical Sciences, Bhubaneswar, Bhubaneswar 751019, Odisha, India
Author contributions: Pramanik S performed the literature search, wrote the first draft, and provided intellectual input; Pal P conceptualized the work, performed a literature search, and supervised the writing; Ray S supervised the literature search, and the writing, provided intellectual input and critically revised the manuscript.
Conflict-of-interest statement: All authors have no conflicts of interest to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Sayantan Ray, MBBS, MD, Assistant Professor, Department of Endocrinology, All India Institute of Medical Sciences, Bhubaneswar, Sijua, Patrapada, Bhubaneswar 751019, Odisha, India. sayantan.ray30@gmail.com
Received: December 27, 2023 Peer-review started: December 27, 2023 First decision: January 5, 2024 Revised: January 20, 2024 Accepted: February 27, 2024 Article in press: February 27, 2024 Published online: June 20, 2024 Processing time: 170 Days and 5 Hours
Core Tip
Core Tip: Co-existence of non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) synergistically act to increase the risk of adverse hepatic and extra hepatic outcomes. T2DM is an established risk factor for NAFLD progression to NASH, advanced fibrosis or cirrhosis. Timely intervention in these populations could have a significant effect on liver- related outcomes. Newer dual and pan-PPAR agonists show promising results in patients with NAFLD/NASH and T2DM. Incretin-based therapy for the treatment of NAFLD is currently being explored. With better understanding of the complex interaction between T2DM and NAFLD, PPAR agonists and incretin-based therapies are likely to provide more effective approach of NAFLD management in T2DM.
